Real-life use of delamanid: results from the European post-authorisation safety study
BACKGROUND: A post-authorisation safety gildan antique orange study (PASS) on delamanid (DLM) was conducted as part of a post-approval commitment to the European Medicines Agency.The aim of this study was to evaluate the use of DLM in a real-life setting, its safety, and treatment outcomes in patients with multidrug-resistant TB (MDR-TB).METHODS: T